Gambaran Umum
Palisade Bio, Inc. is a biopharmaceutical company based in the United States, primarily focused on the development of therapeutics to address acute and chronic gastrointestinal (GI) complications stemming from post-operative digestive enzyme damage. The company is chiefly engaged in advancing its portfolio through clinical trials aimed at enhancing recovery and preventing complications following GI surgery. One of their key projects includes the development of an investigational drug, LB1148, which is designed to accelerate the return of GI function post-surgery, potentially reducing the need and associated risks of intravenous nutrition and opioids. This focus is part of Palisade Bio’s broader strategy to address significant unmet medical needs in post-operative care.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai operating income untuk Palisade Bio, Inc. per 2025 Jun 30 adalah -12.13 MM.
- Nilai net income untuk Palisade Bio, Inc. per 2025 Jun 30 adalah -11.85 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | -12.13 | -11.85 | |
2025-03-31 | -13.50 | -13.14 | |
2024-12-31 | -14.86 | -14.44 | |
2024-09-30 | 0.00 | -14.41 | -14.06 |
2024-06-30 | 0.00 | -14.59 | -14.17 |
2024-03-31 | 0.00 | -13.99 | -13.49 |
2023-12-31 | 0.25 | -12.85 | -12.30 |
2023-09-30 | 0.25 | -13.76 | -13.05 |
2023-06-30 | 0.25 | -13.99 | -13.44 |
2023-03-31 | 0.25 | -13.95 | -12.39 |
2022-12-31 | -15.31 | -14.26 | |
2022-09-30 | -15.49 | -9.47 | |
2022-06-30 | -14.50 | 2.61 | |
2022-03-31 | -13.67 | -26.79 | |
2021-12-31 | -11.74 | -26.62 | |
2021-09-30 | -10.96 | -31.93 | |
2021-06-30 | -9.76 | -41.86 | |
2021-03-31 | -8.86 | -11.97 | |
2020-12-31 | -9.30 | -10.32 | |
2020-09-30 | -9.06 | -8.94 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Palisade Bio, Inc. pada 2025 Jun 30 adalah -3.57.
- laba per saham yang terdilusi untuk Palisade Bio, Inc. pada 2025 Jun 30 adalah -3.57.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -3.57 | -3.57 |
2025-03-31 | -5.42 | -5.42 |
2024-12-31 | -10.19 | |
2024-09-30 | -13.65 | -13.64 |
2024-06-30 | -18.25 | -18.25 |
2024-03-31 | -23.44 | -23.44 |
2023-12-31 | -27.01 | |
2023-09-30 | -40.27 | -40.29 |
2023-06-30 | -60.95 | -60.97 |
2023-03-31 | -101.30 | -101.32 |
2022-12-31 | -247.89 | -247.95 |
2022-09-30 | -285.62 | -285.55 |
2022-06-30 | -17.27 | -17.20 |
2022-03-31 | -1,585.64 | -1,888.63 |
2021-12-31 | -2,144.20 | -2,546.13 |
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | -0.12 | -0.12 |
2020-12-31 | ||
2020-09-30 | -242.79 | -242.73 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Palisade Bio, Inc. per 2025 Jun 30 adalah -9.66 MM.
- Nilai kas dari aktivitas pendanaan untuk Palisade Bio, Inc. per 2025 Jun 30 adalah 3.73 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -9.66 | 3.73 | |
2025-03-31 | -11.35 | 7.30 | |
2024-12-31 | -12.19 | 9.58 | |
2024-09-30 | -12.56 | 0.00 | 5.29 |
2024-06-30 | -12.09 | 0.00 | 7.04 |
2024-03-31 | -10.79 | -0.00 | 8.77 |
2023-12-31 | -11.13 | -0.00 | 11.19 |
2023-09-30 | -11.69 | -0.01 | 13.03 |
2023-06-30 | -12.07 | -0.01 | 23.51 |
2023-03-31 | -13.12 | -0.01 | 19.79 |
2022-12-31 | -13.36 | -0.01 | 15.26 |
2022-09-30 | -13.11 | 0.00 | 12.99 |
2022-06-30 | -12.81 | -0.35 | 5.49 |
2022-03-31 | -17.29 | -0.05 | 23.37 |
2021-12-31 | -14.77 | -0.05 | 24.61 |
2021-09-30 | -13.27 | -0.06 | 26.67 |
2021-06-30 | -11.39 | 0.29 | 22.23 |
2021-03-31 | -4.70 | -0.01 | 3.04 |
2020-12-31 | -4.77 | -0.01 | 1.89 |
2020-09-30 | -5.12 | -0.01 | 0.30 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/e untuk Palisade Bio, Inc. pada 2025 Jun 30 adalah -0.23.
- p/libro untuk Palisade Bio, Inc. pada 2025 Jun 30 adalah 0.56.
- p/tbv untuk Palisade Bio, Inc. pada 2025 Jun 30 adalah 0.57.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | -0.23 | 0.56 | 0.57 |
2025-03-31 | -0.21 | 0.41 | 0.41 |
2024-12-31 | 0.34 | 0.34 | |
2024-09-30 | -0.28 | 0.40 | 0.40 |
2024-06-30 | -0.32 | 0.43 | 0.43 |
2024-03-31 | 0.32 | 0.32 | |
2023-12-31 | -0.42 | 0.39 | 0.39 |
2023-09-30 | -0.40 | 0.34 | 0.34 |
2023-06-30 | -0.76 | 0.68 | 0.68 |
2023-03-31 | -1.11 | 1.26 | |
2022-12-31 | -0.84 | 0.64 | 0.64 |
2022-09-30 | 1.68 | 1.68 | |
2022-06-30 | -0.33 | 1.85 | 1.85 |
2022-03-31 | -0.73 | 2.62 | 2.62 |
2021-12-31 | -0.57 | 4.60 | 4.60 |
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Palisade Bio, Inc. pada 2025 Jun 30 adalah 3.18.
- EBIT (3 tahun) / EV untuk Palisade Bio, Inc. pada 2025 Jun 30 adalah 3.28.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | 3.18 | 3.28 |
2025-03-31 | 2.16 | 2.01 |
2024-12-31 | 2.54 | 2.44 |
2024-09-30 | 2.02 | 1.74 |
2024-06-30 | 1.97 | 2.57 |
2024-03-31 | 1.43 | 2.06 |
2023-12-31 | 1.36 | 1.89 |
2023-09-30 | 1.26 | 1.65 |
2023-06-30 | 3.23 | 4.48 |
2023-03-31 | -4.11 | -5.09 |
2022-12-31 | 1.67 | 2.96 |
2022-09-30 | 0.96 | -4.71 |
2022-06-30 | -11.60 | -11.36 |
2022-03-31 | -2.98 | -1.82 |
2021-12-31 | -7.07 | -3.86 |
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | ||
2020-09-30 |
Efektivitas Manajemen
- roa untuk Palisade Bio, Inc. pada 2025 Jun 30 adalah -1.02.
- roe untuk Palisade Bio, Inc. pada 2025 Jun 30 adalah -1.32.
- roic untuk Palisade Bio, Inc. pada 2025 Jun 30 adalah -2.40.
- croic untuk Palisade Bio, Inc. pada 2025 Jun 30 adalah -0.74.
- ocroic untuk Palisade Bio, Inc. pada 2025 Jun 30 adalah -2.07.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -1.02 | -1.32 | -2.40 | -0.74 | -2.07 |
2025-03-31 | -1.14 | -1.43 | -1.88 | -0.34 | -1.59 |
2024-12-31 | -1.00 | -1.24 | -2.01 | -1.04 | -1.80 |
2024-09-30 | -0.83 | -1.01 | -1.36 | -0.48 | -1.16 |
2024-06-30 | -0.88 | -0.98 | -1.30 | -0.19 | -1.04 |
2024-03-31 | -0.78 | -0.99 | -1.05 | 0.00 | -0.95 |
2023-12-31 | -0.80 | -1.05 | -0.89 | 0.09 | -0.80 |
2023-09-30 | -1.72 | -3.19 | -0.82 | 0.69 | -0.73 |
2023-06-30 | -1.59 | -2.94 | -0.83 | 0.71 | -0.75 |
2023-03-31 | -1.71 | -2.98 | -0.88 | 0.47 | -0.93 |
2022-12-31 | -0.58 | -2.42 | -0.72 | -0.01 | -1.00 |
2022-09-30 | 0.16 | 0.67 | -0.71 | -0.01 | -0.98 |
2022-06-30 | -1.79 | 0.56 | -1.65 | -2.75 | |
2022-03-31 | -8.01 | -5.42 | 1.22 | -3.50 | |
2021-12-31 | -10.58 | -3.30 | 1.21 | -2.84 | |
2021-09-30 | -33.54 | -6.10 | |||
2021-06-30 | -10.05 | -35.75 | |||
2021-03-31 | -2.87 | -10.22 | |||
2020-12-31 | -2.47 | -3.17 | |||
2020-09-30 |
Gross Margins
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | 1.00 | -49.20 | -51.38 |
2023-12-31 | 1.00 | -52.20 | -53.61 |
2023-09-30 | 1.00 | -53.78 | -55.96 |
2023-06-30 | 1.00 | -53.78 | -55.96 |
2023-03-31 | -49.58 | -55.81 | |
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1357459 |
Grupong Pang-industriya
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech) |